	US 12,250,943 B2
	Compositions and methods for the cryopreservation of immune cells
Yosef Refaeli, Denver, CO (US); Brian C. Turner, Denver, CO (US); and Thomas R. Payne, Aurora, CO (US)
Assigned to HTYR Acquisition LLC, Philadelphia, PA (US)
Appl. No. 17/602,207
Filed by HTYR Acquistion LLC, Philadelphia, PA (US)
PCT Filed Apr. 7, 2020, PCT No. PCT/US2020/027070 § 371(c)(1), (2) Date Oct. 7, 2021, PCT Pub. No. WO2020/210231, PCT Pub. Date Oct. 15, 2020.
Claims priority of provisional application 62/830,950, filed on Apr. 8, 2019.
Prior Publication US 2022/0142149 A1, May 12, 2022
Int. Cl. A01N 1/02 (2006.01); C12N 5/078 (2010.01)

CPC A01N 1/0221 (2013.01) [A01N 1/0284 (2013.01); C12N 5/0634 (2013.01)]

24 Claims

1. A cryogenically frozen composition comprising:

(a) a MYC fusion polypeptide, comprising (i) a protein transduction domain; (ii) a MYC polypeptide sequence; and

(b) one or more peripheral blood mononuclear cells (PBMCs) isolated from a donor subject;

wherein the composition exhibits increased cell viability when thawed as compared to control PBMCs in the absence of the MYC fusion polypeptide after a freeze-thaw cycle.